AIM ImmunoTech Announces Positive Study Findings
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen.
Additional commentary published discussing the potential of Ampligen and two other drugs.
AIM ImmunoTech Inc. (NYSE American: AIM) today announced the official print publication of the data analysis from a long-term Early Access Program studying the company’s drug Ampligen for the treatment of advanced pancreatic ductal adenocarcinoma. The manuscript titled Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses, appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals.
Ampligen's Functionality and Impact
Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on various immune cells, epithelial cells, and tumors. Researchers found that Ampligen treatment in pancreatic cancer patients enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1s) and T cells. The increased peripheral abundance correlated with improved clinical outcomes, showcasing notable overexpression of genes related to DC and T cell activation.
“We are grateful to the Erasmus team for their continued contributions to the advancement of Ampligen,” said AIM Chief Executive Officer Thomas K. Equels. “There remains a large and growing unmet need for safe and effective treatments for pancreatic cancer. This data continues to provide us with insight into Ampligen’s ability to improve progression-free and overall survival.”
Expert Insights on Ampligen
Prof. Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon added, “We continue to be encouraged by this data suggesting Ampligen infusions modulate PD-L1 and PD-L2 expression in the tumor microenvironment, while upregulating Ki67+CD4+ and Ki67+CD8+ T-cells. We are making progress in the ongoing DURIPANC trial, investigating the combination effect of Ampligen and other therapies.”
Recent Commentary and Future Trials
In addition to the published manuscript, further commentary discusses the potential of Ampligen and two other drugs. Key highlights include:
- Ampligen has been safely administered through a systemic route.
- Significant increases in cDC1 numbers and cytokines governing T-cell activation and migration were noted.
- Researchers observed important enrichment of B-cell numbers in the peripheral blood, correlating with long-term survival.
AIM is currently evaluating Ampligen for metastatic pancreatic ductal adenocarcinoma in the Phase 1b/2 DURIPANC clinical study and for locally advanced pancreatic adenocarcinoma in the Phase 2 AMP-270 clinical study.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19. The company’s lead product is a first-in-class investigational drug called Ampligen, a dsRNA TLR3 agonist with broad-spectrum activity in clinical trials for globally significant health issues.
For more information, please visit aimimmuno.com or connect with the Company on social media.
Frequently Asked Questions
What is Ampligen used for?
Ampligen is being evaluated as a treatment for advanced pancreatic cancer and other conditions through its immune-stimulatory properties.
What were the findings of the study?
The study showed that Ampligen improved immune activity and clinical outcomes in pancreatic cancer patients.
Who conducted the research on Ampligen?
The research was carried out by the Erasmus University Medical Center.
What is the significance of TLR-3 activation?
TLR-3 activation enhances immune responses, potentially improving cancer treatment outcomes.
How can I learn more about AIM ImmunoTech?
You can find more information on AIM ImmunoTech by visiting their website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/